-
Mashup Score: 12
Vol. 21 Issue 12 p3304 – 3316 Nicola J. Mutch Robert L. Medcalf Fibrinolysis is the system primarily responsible for removal of fibrin deposits and blood clots in the vasculature. The terminal enzyme in the pathway, plasmin, is formed from its circulating precursor, plasminogen. Fibrin is by far the most legendary substrate, but plasmin is notoriously prolific and is known to cleave many other proteins and participate in the activation of other proteolytic systems. Fibrinolysis is often overshadowed by
Source: www.jthjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Involvement of peptidylarginine deiminase 4 in eosinophil extracellular trap formation and contribution to citrullinated histone signal in thrombi - 3 month(s) ago
Extracellular traps formed by neutrophils (NETs) and eosinophils (EETs) have been described in coronary thrombi, contributing to thrombus stability. A key mechanism during NET formation is histone modification by the enzyme PAD4. Citrullinated histones, the product of PAD4 activity, are often attributed to neutrophils. Eosinophils also express high levels of PAD4 but the contribution of PAD4 to EET formation is not known.
Source: www.jthjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
Vol. 21 Issue 12 p3304 – 3316 Nicola J. Mutch Robert L. Medcalf Fibrinolysis is the system primarily responsible for removal of fibrin deposits and blood clots in the vasculature. The terminal enzyme in the pathway, plasmin, is formed from its circulating precursor, plasminogen. Fibrin is by far the most legendary substrate, but plasmin is notoriously prolific and is known to cleave many other proteins and participate in the activation of other proteolytic systems. Fibrinolysis is often overshadowed by
Source: www.jthjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Reducing the risk of atherosclerotic cardiovascular disease in people with haemophilia, the importance of primary prevention. - 3 month(s) ago
Revolutionary advances in the treatment of haemophilia has led to a significant improvement in life expectancy. Associated with this has been an increase in age-related diseases especially atherosclerotic cardiovascular disease (CVD). While people with haemophilia (PWH) develop atherosclerosis at rates similar to the general population, rates of atherothrombosis and mortality related to CVD have been much lower, due to their hypocoagulable state. Changing treatment paradigms, aimed at reducing the risk of bleeding by improving haemostasis to levels approaching normality, has meant the protection they are thought to have had may be lost.
Source: www.jthjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
Vol. 21 Issue 12 p3304 – 3316 Nicola J. Mutch Robert L. Medcalf Fibrinolysis is the system primarily responsible for removal of fibrin deposits and blood clots in the vasculature. The terminal enzyme in the pathway, plasmin, is formed from its circulating precursor, plasminogen. Fibrin is by far the most legendary substrate, but plasmin is notoriously prolific and is known to cleave many other proteins and participate in the activation of other proteolytic systems. Fibrinolysis is often overshadowed by
Source: www.jthjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Vol. 21 Issue 12 p3304 – 3316 Nicola J. Mutch Robert L. Medcalf Fibrinolysis is the system primarily responsible for removal of fibrin deposits and blood clots in the vasculature. The terminal enzyme in the pathway, plasmin, is formed from its circulating precursor, plasminogen. Fibrin is by far the most legendary substrate, but plasmin is notoriously prolific and is known to cleave many other proteins and participate in the activation of other proteolytic systems. Fibrinolysis is often overshadowed by
Source: www.jthjournal.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Antiplatelet strategies: past, present, and future - 4 month(s) ago
Antiplatelet therapy plays a critical role in the prevention and treatment of major cardiovascular diseases triggered by thrombosis. Since the 1900s, significant progress in reducing morbidity and death caused by cardiovascular diseases has been made. However, despite the development and approval of drugs that specifically target the platelet, including inhibitors for cycloxygenase-1, P2Y12 receptor, integrin αIIbβ3, phosphodiesterases, and protease-activated receptor 1, the risk of recurrent thrombotic events remains high, and the increased risk of bleeding is a major concern.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19The fibrinolysis renaissance - 5 month(s) ago
Fibrinolysis is the system primarily responsible for removal of fibrin deposits and blood clots in the vasculature. The terminal enzyme in the pathway, plasmin, is formed from its circulating precursor, plasminogen. Fibrin is by far the most legendary substrate, but plasmin is notoriously prolific and is known to cleave many other proteins and participate in the activation of other proteolytic systems. Fibrinolysis is often overshadowed by the coagulation system and viewed as a simplistic poorer relation.
Source: www.jthjournal.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5Hemophilia gene therapy: first, do no harm - 5 month(s) ago
The introduction of adeno-associated virus–mediated, liver-directed gene therapy into the hemophilia treatment landscape brings not only great promise but also considerable uncertainty to a community that has a history punctuated by the devastating effects of HIV and hepatitis C virus. These infections were introduced into people with hemophilia through the innovation of factor concentrates in the 1970s and 1980s. Concentrates, heralded as a major advance in treatment at the time, brought devastation and death to the community already challenged by the complications of bleeding into joints, vital organs, and the brain.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37Low-dose Emicizumab prophylaxis in severe haemophilia A patients –a retrospective study bringing new hope for our patients. - 5 month(s) ago
– Low-dose Emicizumab can potentially offer a cost-effective treatment option in PwHA especially in developing countries. We evaluated its efficacy and safety when given for six months compared to low-dose Factor VIII prophylaxis in this chart review.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet
Read this special collection of review articles honoring the 20th anniversary of the Journal of Thrombosis and Haemostasis. An impressive collection of reviews from world-renowned experts on some of the most important topics in the field. https://t.co/4dm2L4hjWJ @JTHjournal https://t.co/iQsOR6UVNk